Abstract
Increasing evidence suggests that cancer cells (relative to normal cells) have altered mitochondrial
electron transport chains (ETC) that are more likely to form reactive oxygen species (ROS; i.e. O2
•-and H2O2) resulting in a condition of chronic metabolic oxidative stress, that maybe compensated for
by increasing glucose and hydroperoxide metabolism. In the current study, the ability of an inhibitor of
glucose metabolism, 2-deoxy-D-glucose (2DG), combined with mitochondrial electron transport chain
blockers (ETCBs) to enhance oxidative stress and cytotoxicity was determined in human colon
cancer cells. Treatment of HT29 and HCT116 cancer cells with Antimycin A (Ant A) or rotenone (Rot)
increased carboxy-dichlorodihydrofluorescein diacetate (H2DCFDA) and dihydroethidine (DHE)
oxidation, caused the accumulation of glutathione disulfide and enhanced 2DG-induced cell killing. In
contrast, Rot did not enhance the toxicity of 2DG in normal human fibroblasts supporting the
hypotheses that cancer cells are more susceptible to inhibition of glucose metabolism in the presence
of ETCBs. In addition, 2-methoxy-antimycin A (Meth A; an analog of Ant A that does not have ETCB
activity) did not enhance 2DG-induced DHE oxidation or cytotoxicity in cancer cells. Finally, in HT29
tumor bearing mice treated with the combination of 2DG (500 mg/kg) + Rot (2 mg/kg) the average
rate of tumor growth was significantly slower when compared to control or either drug alone. These
results show that 2DG-induced cytotoxicity and oxidative stress can be significantly enhanced by
ETCBs in human colon cancer cells both in vitro and in vivo.